∗Servicio de Farmacia Hospitalaria, Institut Català de Oncologia
†Servicio de Farmacia Hospitalaria, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat
‡Servicio de Neurología, Unidad de Epilèpsia, Hospital Universitari de Bellvitge, Neuroscience Program, Neurology and Neurogenetics Group, IDIBELL Grup de L'Hospitalet de Llobregat
§Laboratorio Clínico, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat
∥Servicio de Neurología, Unidad de Epilèpsia, Hospital Universitari de Bellvitge, Neuroscience Program, Cognition and Plasticity Group, IDIBELL Grup de L'Hospitalet de Llobregat, Barcelona, Spain.
Address correspondence and reprint requests to Sara Otero Torres, PharmD, Servicio de Farmacia Hospitalaria, Institut Català de Oncologia, Hospital Duran i Reynals 1, Avinguda de la Granvia de l'Hospitalet, 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain; E-mail: [email protected]
Conflicts of Interest and Source of Funding: The authors have no conflicts of interest to declare.
Compliance with Ethical Standards Statement: The protocol was approved by Hospital Universitari de Bellvitge Research and Ethics Committee.
Author Contributions: All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Sara Otero Torres and Roser Juvany Roig. The first draft of the manuscript was written by Sara Otero Torres, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
